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Background/purpose: To evaluate the efﬁcacy of ketoconazole in castration-resistant prostate cancer.
Materials and methods: We reviewed the medical records of consecutive patients with pathologically
conﬁrmed prostate cancer from May 2006 to December 2008. The inclusion criteria were: (1) receiving
200 or 400 mg ketoconazole three times daily and replacement doses of prednisolone; (2) antiandrogen
withdrawal for at least 2 months before ketoconazole treatment; and (3) no prior cytotoxic agents or
other CYP17 inhibitors. Treatment consisted of ketoconazole at 200 mg three times daily (Group A) and
400 mg three times daily (Group B). Patients’ characteristics, time to prostate-speciﬁc antigen (PSA)
progression, duration of PSA response, and adverse events were evaluated.
Results: Of the 37 patients in Group A, 14 (37.8%) experienced a PSA response. Of the seven patients in
Group B, four (57.1%) experienced a PSA response. Median durations of time to progression in those who
experienced a > 50% PSA decline were 7.5 and 11.5 months in Group A and Group B, respectively. Median
duration of PSA response was 5.5 and 9.0 months in Group A and Group B, respectively. There was no
difference in the PSA response or time to progression between the two groups. Orchiectomy had
a borderline unfavorable effect on the PSA response rate (p ¼ 0.067).
Conclusion: The present study demonstrated that ketoconazole contributed to the PSA response in
patients with castration-resistant prostate cancer. The efﬁcacy and toxicity proﬁles were comparable to
those in previous studies. Orchiectomy had a borderline unfavorable effect on PSA response rate. Further
studies are required to conﬁrm the efﬁcacy of ketoconazole therapy in surgically castrated patients.
Copyright  2012, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Androgen deprivation therapy can achieve a castration status for
a period, but prostate cancer eventually progresses to castration
resistance. Several mechanisms allow androgen receptor signaling
to persist. It is believed that androgen receptors are frequently
overexpressed and appear to be activated by castration levels of
androgen and adrenal androgens.1 The adrenal glands secrete
w10% of the circulating androgen in humans. Ketoconazole,
a broad-spectrum azole antifungal agent, inhibits cytochrome P-
450 and suppresses testicular and adrenal androgen production
through inhibiting both adrenocortical 11b-hydroxylase and
cholesterol side-chain cleavage.2 A phase III trial (CALGB 9583) has
demonstrated that antiandrogen withdrawal (AAWD) together
with high-dose ketoconazole, 400 mg three times daily, andNational Taiwan University
Medicine, No. 7, Chung-Shan
uang).
ciation. Published by Elsevier Taiwhydrocortisone, 30 mg each morning and 10 mg each evening, was
associated with an objective prostate-speciﬁc antigen (PSA)
response, and 8.6 months median time to PSA progression in 32% of
128 patients with castration-resistant prostate cancer (CRPC).3
Low-dose ketoconazole, at 200 mg three times daily, with
replacement doses of hydrocortisone (20 mg every morning and
10 mg at bedtime), was associated with a PSA response and 30
weeks median duration of PSA response in 46% of 28 patients.4
Here, we conducted a retrospective study to share our experi-
ence of using ketoconazole in patients with CRPC at National
Taiwan University Hospital. The toxicity proﬁles and predictors of
the PSA response were also evaluated.
2. Materials and methods
We retrospectively reviewed the medical records of consecutive
patients with CRPC from May 2006 to December 2008. The deﬁni-
tion of CRPC was based on European Association of Urology guide-
lines.5 The inclusion criteria were: (1) receiving 200 or 400 mg
ketoconazole three times daily and replacement doses ofan LLC. Open access under CC BY-NC-ND license.
Table 2
Clinical outcomes in the separate groups.
Group A Group B p value
AAWD response 8 1 0.644
50% PSA decline, n (%) 14 (37.8%) 4 (57.1%) 0.175
75% PSA decline, n (%) 8 (21.6%) 1 (14.3%) 0.585
Among 50% PSA decline
Median time to progression,
mo (range)
7.5 (1e87) 11.5 (4e16.5) 1
Median duration of PSA
response, mo (range)
5.5 (0.5e86) 9.0 (2e13) 1
Group A, 200 mg ketoconazole three times daily; Group B, 400 mg ketoconazole
three times daily; AAWD ¼ antiandrogen withdrawal; PSA ¼ prostate-speciﬁc
antigen.
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treatment; and (3) no prior cytotoxic agents or other CYP17
inhibitors.
Patients’ characteristics, time to PSA progression, duration of
PSA response, and toxicity proﬁles were evaluated according to
guidelines of the Prostate Speciﬁc Antigen Working Group and
National Cancer Institute Common Toxicity Criteria.6
Results were analyzed with commercial statistical software. Age
and PSA were compared using the median test. Categorical data
were compared using a c2 test and Fisher’s exact test. For all tests,
a two-tailed p value <0.05 was regarded as signiﬁcant.
3. Results
3.1. Patient characteristics
In total, 44 patients with CRPCwere included, with amedian age
of 73 years (range, 55e88 years). Median serum PSA at diagnosis of
prostate cancer was 74.5 ng/mL (range, 4.3e3310 ng/mL). Four
patients (9.1%) underwent radical prostatectomy as deﬁnitive local
therapy at the time of prostate cancer diagnosis, and 10 patients
(22.7%) underwent external beam radiotherapy. At the start of
ketoconazole therapy, 36 patients (81.8%) had bone metastasis, and
the median PSA level was 30.9 ng/mL (range, 5.2e350.2 ng/mL).
Thirty-eight patients (86.4%) received luteinizing hormone
releasing hormone agonist (LHRHa), and two patients (4.5%)
underwent bilateral orchiectomy as androgen deprivation therapy.
Four patients (9.1%) received LHRHa and subsequent bilateral
orchiectomy. Initial Gleason scores are given in Table 1. The mean
duration of hormone therapy before ketoconazole therapy was 32
months (range, 6e208 months). Patient characteristics were cate-
gorized into ketoconazole 200 mg three times daily (Group A) and
400 mg three times daily (Group B) and are listed in Table 1. There
were no signiﬁcant differences in patients’ characteristics between
the groups.Table 1
Patient characteristics categorized into Group A (ketoconazole 200 mg three times
daily) and Group B (ketoconazole 400 mg three times daily).
Group A Group B
Median age, yr (range) 73 (55e88) 76 (59e86)
Median PSA, ng/mL,
at diagnosis (range)
92.6 (4.3e3310) 74.5 (13.9e330.5)
Median PSA, ng/mL, at initiation
of ketoconazole (range)
29.5 (5.2e350.2) 32.2 (13.8e221.2)
Median duration (mo) between
diagnosis of prostate cancer and
initiating ketoconazole (range)
30 (6e174) 32 (6e204)
Gleason score, n
4e6 5 2
7 10 1
8e10 19 4
Deﬁnitive local therapy, n
Radical prostatectomy 4 0
Radiotherapy 8 2
Castration therapy
LHRHa 31 7
Orchiectomy 2 0
LHRHa and subsequent
orchiectomy
4 0
Metastasis before ketoconazole
Bone metastasis 20 5
Bone and soft-tissue metastasis 10 1
Soft-tissue metastasis only 2 0
LHRHa ¼ luteinizing hormone releasing hormone agonist.3.2. Clinical outcomes
Of the 44 patients, 37 patients received 200 mg ketoconazole
three times daily (Group A), and seven patients received 400 mg
ketoconazole three times daily (Group B). Eighteen patients expe-
rienced a PSA decline of 50% after ketoconazole therapy. Of the 37
patients in Group A, 14 (37.8%) had a  50% PSA decline, and eight
(21.6%) had a  75% PSA decline. Of the seven patients in Group B,
four (57.1%) had a  50% PSA decline, and one (14.3%) had a  75%
PSA decline. There was no signiﬁcant difference between the two
groups. Median time to progression in those who experienced
a > 50% PSA decline was 7.5 months and 11.5 months in Group A
and Group B, respectively. Median duration of PSA responsewas 5.5
and 9.0 months in Group A and Group B, respectively. There were
no differences in the time to progression or duration of the PSA
response between the two groups. Clinical outcomes for the
separate groups are listed in Table 2.
Clinical factors of those with a > 50% response and the others
were compared. Neither age (p ¼ 0.417), initial PSA level
(p ¼ 0.651), duration between diagnosis of prostate cancer and
initiation of ketoconazole (p ¼ 0.759), PSA level on initiation of
ketoconazole (p ¼ 0.759), prior radical prostatectomy (p ¼ 1.0),
prior radiotherapy (p ¼ 0.504), prior LHRHa (p ¼ 0.634), prior
orchiectomy (p ¼ 0.067), metastasis at diagnosis (p ¼ 0.515), nor
Gleason score (p¼ 0.14) could independently predict PSA response.
4. AAWD response
Nine patients (20.5%) experienced AAWD response before
treatment with ketoconazole. There was no signiﬁcant difference
between the two groups.
4.1. Adverse events
Table 3 shows a summary of adverse events during treatment
with ketoconazole. Of the 44 patients, 13 (29.5%) experienced
adverse events. The most common adverse event was elevation of
the liver function. Four patients (9.1%) had grade 1/2, and one
patient had grade 3 elevated liver function. The patientTable 3
Summary of adverse events during treatment with ketoconazole.
Adverse event Grade 1/2 Grade 3
Fatigue 2 e
Arrhythmia 1 e
Vertigo 1 e
Epigastralgia 2 e
Nausea 1 e
Headache 1 e
Elevation of liver function 4 1
Two patients in Group B experienced adverse events of nausea and vertigo.
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treatment. Two patients (4.5%) had grade 1/2 fatigue. One (2.3%)
patient had grade 1 arrhythmia and stopped treatment. One (2.3%)
patient had grade 1 vertigo. Two patients (4.5%) had epigastralgia
and stopped treatment. One (2.3%) patient had grade 1 nausea. One
(2.3%) patient had grade 1 headache. There was no signiﬁcant
difference in the total number of adverse events between the two
groups (p ¼ 1.0). Four patients (9.1%) terminated treatment with
ketoconazole due to adverse events, all of whom were in Group A.
5. Discussion
Previous studies have reported the use of a > 50% decrease in
PSA as an intermediate marker of survival.7e9 Mark et al have
reported that a > 75% decline in PSA in response to high-dose
ketoconazole therapy predicts better survival.10 Table 4 lists
biochemical response rates of ketoconazole therapy reported in the
literature. The use of ketoconazole as secondary hormone manip-
ulation therapy for CRPC achieved 27e63% PSA responses.4,9e13 In
the present study, we demonstrated the PSA response to different
doses of ketoconazole therapy: 37.8% and 21.6% of patients who
received 200 mg ketoconazole three times daily experienced> 50%
and > 75% PSA declines, and 57.1% and 14.3% of patients who
received 400 mg ketoconazole three times daily experienced> 50%
and > 75% PSA declines, respectively. The number of patients in
Group B who tended to achieve  50% PSA decline was insigniﬁ-
cant, perhaps because of the low case number.
Ketoconazole suppresses androgen production in the testes and
adrenal gland. In the CALGB 9583 study,3 the largest prospective
study to evaluate adrenal androgen levels in patients treated with
ketoconazole,dehydroepiandrosterone (DHEA) and androstene-
dione achieved a modest increase in adrenal androgen levels at the
time to progression. Suppression of androgen was partially
reversed at the time of disease progression. Additional responses
occurred in some patients after dose escalation.14 The biochemical
response was inﬂuenced by the dose of ketoconazole. This suggests
that the dose might be insufﬁcient to suppress production of
adrenal androgen in those patients who had no PSA response.
However, in the present study, we failed to determine statistically if
more patients who received 400 mg ketoconazole three times daily
had a PSA response than those who received 200 mg three times
daily due to the small sample size. Ketoconazole absorption from
the gastrointestinal tract is variable. Its dissolution is dependent on
gastric acidity. The elimination half-life is 6.5e10 hours. Changes in
plasma testosterone levels vary among individuals,15 and the ability
to measure serum ketoconazole levels is still unavailable. Consid-
ering the adverse effects, the dose of ketoconazole should be
individualized. Therapy can begin with a low dose of ketoconazole
that is well tolerated and has moderate activity.4 Subsequent
escalation to a high dose can be applied if patients encounter PSA
progression.14Table 4
Studies of ketoconazole therapy in castration-resistant prostate cancer.
Reference No. of cases Dosage Percent of subjects
with50% PSA decline
Small et al. (1997) 48 400 mg tid 63%
Harris et al. (2001) 28 200 mg tid 46%
Millikan et al. (2001) 45 400 mg tid 40%
Small et al. (2004) 128 400 mg tid 27%
Wilkinson et al. (2004) 38 300 mg tid 55%
Scholz et al. (2005) 78 400 mg tid 44% of subjects had
a75%PSA decline
Chiang et al. (2011) 37 200 mg tid 37.8%
PSA ¼ prostate-speciﬁc antigen; tid ¼ three times daily.None of the six patients who underwent an orchiectomy in the
present study had a PSA response, although there was a borderline
unfavorable effect on the PSA response rate (p ¼ 0.067). Oka et al
have reported that LHRHa signiﬁcantly decreases serumDHEA,
whereas orchiectomy does not decrease serum DHEA.16 This
suggests that patients receiving simultaneous LHRHa and keto-
conazole therapy might tend to have a PSA response. Previous
studies have failed to demonstrate the impact of surgical castra-
tion on the PSA response rate.4,9e12 Further studies are required to
determine the efﬁcacy of ketoconazole therapy in surgically cas-
trated patients.
In the present study, 29.5% of patients experienced adverse
events during treatment. Four patients stopped ketoconazole due
to adverse events. Two of the four patients had epigastralgia. One
patient experienced grade 3 elevation of liver function. One patient
had arrhythmia. All of these patients were in Group B. In the CALGB
9583 study,3 21% of patients receiving 400 mg ketoconazole three
times daily had grade 3/4 toxicity. Fatigue and neurotoxicity were
the most common adverse effects and were seen in 4% of patients.
In this study, the most common adverse events were elevation of
liver function, epigastralgia, and fatigue.
Abiraterone acetate, a more potent adrenolytic agent, was
recently approved by the US Food and Drug Administration for
treating metastatic CRPC in men with prior docetaxel chemo-
therapy. It also inhibits 17 a-hydroxylase/C17,20 lyase and results in
suppression of subsequent formation of DHEA and androstene-
dione. The inhibition of androgen biosynthesis prolonged the
overall survival by about 4 months in a phase III study.17 Although
new adrenolytic agents have been developed in the past decade,
ketoconazole still plays a role in treating CRPC because it is less
expensive and is involved in new treatment schemes.18
Our study had several limitations. This was a retrospective study
inwhich the authors reviewed the medical records of patients with
CRPC. It lacked demographic data, including Eastern Cooperative
Oncology Group performance status scores, and patient compliance
data. The administration of replacement doses of prednisolone also
lacked consistency and varied among physicians.
In conclusion, the present study demonstrated that ketocona-
zole contributed to the PSA response in patients with CRPC. The
efﬁcacy and toxicity proﬁles were comparable to those in previous
studies. Orchiectomy had a borderline unfavorable effect on the
PSA response rate. Further studies are required to conﬁrm the
efﬁcacy of ketoconazole therapy in surgically castrated patients.
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